Clinical Trial

Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccines

Completed
View on ClinicalTrials.gov →
Summary
This study aims to evaluate whether oral probiotic supplementation can modulate the immune response induced by COVID-19 vaccination. Specifically, the study will assess the effects of probiotics on vaccine-induced antibody responses and cellular immune responses, and explore whether probiotics may enhance or accelerate immunity and reduce vaccine-related adverse effects. A total of 140 participants are planned to be enrolled.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-21.
Trial Details
NCT Number NCT07610512
Lead Sponsor Grape King Bio Ltd.
Collaborators: Taipei Medical University Hospital
Conditions COVID-19, Immune Response
Enrollment 138 participants
Start Date 2021-10-13
Primary Completion 2022-03-31 (estimated)
Study Completion 2022-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-03